These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: outcomes and toxicity. Pollom EL; Alagappan M; von Eyben R; Kunz PL; Fisher GA; Ford JA; Poultsides GA; Visser BC; Norton JA; Kamaya A; Cox VL; Columbo LA; Koong AC; Chang DT Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):918-25. PubMed ID: 25585785 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970 [TBL] [Abstract][Full Text] [Related]
9. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019 [TBL] [Abstract][Full Text] [Related]
10. Early outcomes of MR-guided SBRT for patients with recurrent pancreatic adenocarcinoma. Poiset SJ; Shah S; Cappelli L; Anné P; Mooney KE; Werner-Wasik M; Laufer TS; Posey JA; Lin D; Basu Mallick A; Lavu H; Bashir B; Yeo CJ; Mueller AC Radiat Oncol; 2024 May; 19(1):65. PubMed ID: 38812040 [TBL] [Abstract][Full Text] [Related]
11. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery. Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321 [TBL] [Abstract][Full Text] [Related]
12. Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer. Lin JC; Jen YM; Li MH; Chao HL; Tsai JT Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):259-64. PubMed ID: 25629569 [TBL] [Abstract][Full Text] [Related]
13. Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer. Lischalk JW; Burke A; Chew J; Elledge C; Gurka M; Marshall J; Pishvaian M; Collins S; Unger K J Gastrointest Cancer; 2018 Jun; 49(2):116-123. PubMed ID: 28044263 [TBL] [Abstract][Full Text] [Related]
14. EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Sanders MK; Moser AJ; Khalid A; Fasanella KE; Zeh HJ; Burton S; McGrath K Gastrointest Endosc; 2010 Jun; 71(7):1178-84. PubMed ID: 20362284 [TBL] [Abstract][Full Text] [Related]
15. Linac-based SBRT as a feasible salvage option for local recurrences in previously irradiated prostate cancer. Cuccia F; Nicosia L; Mazzola R; Figlia V; Giaj-Levra N; Ricchetti F; Rigo M; Vitale C; Corradini S; Ruggieri R; Alongi F Strahlenther Onkol; 2020 Jul; 196(7):628-636. PubMed ID: 32399638 [TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer. Su TS; Liang P; Lu HZ; Liang JN; Liu JM; Zhou Y; Gao YC; Tang MY World J Gastroenterol; 2015 Jul; 21(26):8156-62. PubMed ID: 26185389 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma. Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK Clin Oncol (R Coll Radiol); 2022 Jun; 34(6):386-394. PubMed ID: 34974972 [TBL] [Abstract][Full Text] [Related]
20. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]